Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.
A novel multi-marker discovery approach identifies new serum biomarkers for Parkinson's disease in older people: an EXosomes in PArkiNson Disease (EXPAND) ancillary study.

  • Calvani R
  • Picca A
  • Landi G
  • Marini F
  • Biancolillo A
  • Coelho-Junior HJ
  • Gervasoni J
  • Persichilli S
  • Primiano A
  • Arcidiacono A
  • Urbani A
  • Bossola M
  • Bentivoglio AR
  • Cesari M
  • Bernabei R
  • Monaco MRL
  • Marzetti E
Logopenic aphasia due to Lewy body disease dramatically improved with donepezil.

  • Kakinuma K
  • Baba T
  • Ezura M
  • Endo K
  • Saito Y
  • Narita W
  • Iizuka O
  • Nishio Y
  • Kikuchi A
  • Hasegawa T
  • Aoki M
  • Suzuki K
Pick's disease: clinicopathologic characterization of 21 cases.

  • Choudhury P
  • Scharf EL
  • Paolini MA 2nd
  • Graff-Radford J
  • Alden EC
  • Machulda MM
  • Jones DT
  • Fields JA
  • Murray ME
  • Graff-Radford NR
  • Constantopoulos E
  • Reichard RR
  • Knopman DS
  • Duffy JR
  • Dickson DW
  • Parisi JE
  • Josephs KA
  • Petersen RC
  • Boeve BF
Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction.

  • Yu Z
  • Shi M
  • Stewart T
  • Fernagut PO
  • Huang Y
  • Tian C
  • Dehay B
  • Atik A
  • Yang D
  • De Giorgi F
  • Ichas F
  • Canron MH
  • Ceravolo R
  • Frosini D
  • Kim HJ
  • Feng T
  • Meissner WG
  • Zhang J
Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.

  • Gupta V
  • Salim S
  • Hmila I
  • Vaikath NN
  • Sudhakaran IP
  • Ghanem SS
  • Majbour NK
  • Abdulla SA
  • Emara MM
  • Abdesselem HB
  • Lukacsovich T
  • Erskine D
  • El-Agnaf OMA
Iroquois Homeobox Protein 2 Identified as a Potential Biomarker for Parkinson's Disease.

  • Sim H
  • Lee JE
  • Yoo HM
  • Cho S
  • Lee H
  • Baek A
  • Kim J
  • Seo H
  • Kweon MN
  • Kim HG
  • Jeon YJ
  • Son MY
  • Kim J
Digital Biomarkers of Mobility in Parkinson's Disease During Daily Living.

  • Shah VV
  • McNames J
  • Mancini M
  • Carlson-Kuhta P
  • Nutt JG
  • El-Gohary M
  • Lapidus JA
  • Horak FB
  • Curtze C
Mesial Frontal Lobe Infarction Presenting as Pisa Syndrome.

  • Noda K
  • Ando M
  • Jo T
  • Hattori A
  • Ogaki K
  • Sugiyama M
  • Hattori N
  • Okuma Y

Press releases, workshop summaries, and editorials

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.



NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”